Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2022 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three conditions: (1) paying now for something not yet earning, (2) the wait is the company's main current work, (3) the far side is a specific, near-dated, already-visible event. Let me examine the transcript for evidence. Key topics discussed: - Revenue growth, record Q3 - CMS Final Rule for 2023 — reimbursement increase, but that's a future tailwind, not a current cost - iFuse-TORQ, iFuse Bedrock Granite launches - Granite supply chain issues — "near-term delays in adequate availability of implants" — this is a constraint, not a self-funded waiting period - International underperformance (Germany, UK) — attributed to macro, FX, COVID recovery — outside forces - SAFFRON study — enrolled first patient, results late 2024 — that's a clinical trial, but is it described as a current cost with a near-dated benefit? Results late 2024 is beyond a year, and it's not described as the company's main current work. - Sales force hiring — "we will continue to make those investments but at a moderated pace" — normal investment - Gross margin pressure from new products, trays, freight — these are costs but they're tied to current revenue generation, not a waiting period before a specific arrival. Is there any description of a self-funded interval before a specific near-dated event? The Granite launch is in progress — they're working through hospital approvals and supply chain. But that's presented as a constraint limiting demand capture, not as a cost being borne with a dated far side. The supply chain issue is being worked on, but the far side isn't dated specifically, and it's more of an operational constraint than a chosen waiting period. The CMS reimbursement increase is a future tailwind for 2023, but the company isn't paying for it now — it's a regulatory decision, not a self-funded cost. The SAFFRON study — they're enrolling, results late 2024 — that's beyond a year, and it's not described as the main current work. Nothing in the transcript describes a situation where the company is currently paying real cash for something not yet earning, with a specific near-dated arrival that is the company's main current work.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.